Staphylococcal Toxins in Atopic Dermatitis and Eczema Herpeticum (STADEH)

Poitiers University Hospital

Status

Completed

Conditions

Atopic Dermatitis

Immune Response

Cytokines

Bacterial Toxins

T Cells Subsets

Staphylococcus Aureus

Treatments

Other: Skin biopsies and blood samples

Study type

Interventional

Funder types

Other

Identifiers

NCT04274348

2019-A01904-53

Details and patient eligibility

About

Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. Clinical studies have demonstrated a link between staphylococcal skin colonization and the pathogenesis of AD, but the implication of bacterial virulence factors remains largely uncharacterized. Finally, AD is often associated with herpes simplex skin infections. The aim of this project is to investigate the role of staphylococcal toxins in the exacerbation and maintenance of atopic skin inflammation and in the occurrence of infectious complications such as eczema herpeticum.

Enrollment

41 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with moderate AD (SCORAD between 25 and 50) or severe AD (SCORAD> 50)
Skin lesions in the forearms
Free subject, without neither guardianship, wardship nor subordination
Patient with Social Security
Informed and signed consent by the patient after clear and loyal information on the study

Exclusion criteria

Age < 18 year-old
Patients with mild AD (SCORAD < 25)
Patients without skin lesions in the forearms
Patients treated with dermocorticoid or calcineurin inhibitor for less than two weeks
Patients under systemic treatment : Methotrexate, Ciclosporin, Mycophenolate Mofetil, Azathioprine, general corticosteroids for less than 4 weeks
Patients under biological treatment : Dupilumab for less than 5 half-lives
Patient without Social Security
Pregnant and nursing women